&lt;Medizone International Inc> said itacquired a patent that covers procedures for the use of theMedizone Therapy in deactivating certain viruses commonlyassociated with AIDS, hepatitis and herpes.    The company said the patent covers procedures for thedeactivation of the viruses in human and animal blood, and thetreatment of stored blood prior to transfusion.    Medizone said the acquisition is seen as a significant stepto enhance the company's proprietory position.    The company said the patent was acquired from an unnamedcompany involved in medical research and development for onemillion shares of its common stock. Reuter&#3;